title: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
abstract: BACKGROUND
  Randomized clinical trials have demonstrated the efficacy of adjuvant 5-fluorouracil (5-FU)-based chemotherapy after surgical resection of node-positive colon cancer. Although this treatment became the standard in 1990 following a National Institutes of Health Consensus Conference, among those at least 65 years of age it is less likely to be offered to older or nonwhite patients.
  
  
  OBJECTIVE
  To determine the association between 5-fu-based chemotherapy and survival in older patients.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Combined database of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and Medicare.
  
  
  METHODS
  4768 patients 65 years of age or older who received a diagnosis of node-positive colon cancer from 1992 to 1996, were covered by Medicare Parts A and B, and resided in the population covered by the SEER program.
  
  
  METHODS
  Propensity scores to control for known predictors of receiving treatment, Cox proportional hazards models to assess the association of 5-FU therapy with survival, and sensitivity analyses to estimate the possible effects of unknown confounders.
  
  
  RESULTS
  Fifty-two percent of patients received 5-FU therapy. For this sample, the hazard ratio for death associated with 5-FU therapy was 0.66 (95% CI, 0.60 to 0.73). Confounding could have accounted for this association only if an unmeasured confounder were extremely unequally distributed between the treated and untreated groups or increased mortality by at least 50%.
  
  
  CONCLUSIONS
  5-Fluorouracil adjuvant therapy is significantly associated with reduced mortality in older patients, similar to the association found in randomized, controlled trials among younger patients. More frequent use of 5-FU therapy in older patients would probably reduce death from colon cancer.
authors.affiliation: Joseph L. Mailman School of Public Health, the Herbert Irving Comprehensive Cancer Center, and College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
authors.forename: Vijaya
authors.initials: V
authors.lastname: Sundararajan
authors.forename: Nandita
authors.initials: N
authors.lastname: Mitra
authors.forename: Judith S
authors.initials: JS
authors.lastname: Jacobson
authors.forename: Victor R
authors.initials: VR
authors.lastname: Grann
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Heitjan
authors.forename: Alfred I
authors.initials: AI
authors.lastname: Neugut
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D015986:Confounding Factors, Epidemiologic; D016208:Databases, Factual; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D006278:Medicare; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil